Study of YK012 in B-cell Acute Lymphoblastic Leukemia
A phase 1/2 trial of YK012 in acute lymphoblastic leukaemia, run by Excyte Biopharma Ltd, now recruiting.
Overview
Study of YK012 in B-cell Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT06580301 by Excyte Biopharma Ltd, with 46 participants planned, started 2024-09-25 and due to reach its primary completion in 2026-12-31. Interventions recorded: YK012.
Similar pages
not linked directly; found by shared links- TrialClinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialCAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialAZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Study of CTD402 in T-ALL/LBL Patients
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Shares Acute lymphoblastic leukaemia and the tag pipeline.